Labcorp Holdings Inc. generated $13.01 billion in FY2024 revenue as a global leader in laboratory services, operating through Diagnostics Laboratories (79.2% of revenue) and Biopharma Laboratory Services (20.8% of revenue). The Burlington, North Carolina-based company, formed in 1995 through the merger of Roche Biomedical Laboratories and National Health Laboratories, employs approximately 70,000 people and processes approximately 280 million patient encounters annually.
Labcorp: Key Facts
- Founded: 1995 (modern entity)
- Headquarters: Burlington, North Carolina
- CEO: Adam H. Schechter (appointed November 2019)
- FY2024 Revenue: $13.01 billion
- FY2024 Net Income: $746 million
- Market Capitalization: Approximately $21.4 billion
- Employees: Approximately 70,000
- Segments: Diagnostics Laboratories, Biopharma Laboratory Services
- Stock Listing: NYSE (LH)
- CIK: 0000920148
How Does Labcorp Make Money?
Labcorp generates revenue through two segments. Diagnostics Laboratories contributed approximately $10.31 billion (79.2% of revenue) in FY2024, providing routine testing (blood chemistry, hematology, urinalysis), specialty testing (oncology, women's health, neurology, autoimmune diseases), and pathology services. Biopharma Laboratory Services contributed approximately $2.70 billion (20.8% of revenue), providing central laboratory services for clinical trials, bioanalytical testing, and companion diagnostic development. The company processes approximately 280 million patient encounters annually through a network of primary laboratories, patient service centers, and hospital relationships.
Who Founded Labcorp and When?
Labcorp was formed in 1995 through the merger of Roche Biomedical Laboratories and National Health Laboratories. National Health Laboratories had been founded in the 1970s by James Powell and grown through acquisitions of independent clinical laboratories. Roche Biomedical was the US clinical laboratory subsidiary of Swiss pharmaceutical giant Roche. The merger created the second-largest independent clinical laboratory company in the United States. In 2015, Labcorp acquired Covance for $6.1 billion, and in 2023 spun off its clinical development business as Fortrea.
What Is Labcorp's Competitive Advantage?
Labcorp's primary competitive advantage is its scale in diagnostic testing, processing approximately 280 million patient encounters annually through a national network that competitors cannot easily replicate. The company's longitudinal diagnostic data from more than 75 million patients creates unique assets for analytics and research. Specialty testing capabilities in oncology, women's health, and neurology provide differentiation from commodity routine testing. The Biopharma segment's $7.9 billion backlog provides revenue visibility, while health system partnerships through lab management agreements create sticky customer relationships.
How Has Labcorp's Revenue Grown Over Time?
Labcorp's revenue has grown from approximately $4 billion in the early 2000s to $13.01 billion in 2024. FY2024 revenue of $13.01 billion represented 6.6% growth from $12.20 billion in 2023. The 2015 Covance acquisition added approximately $2.5 billion in biopharma services revenue, while the 2023 Fortrea spin-off removed approximately $3 billion in clinical development revenue. The 2026 guidance calls for revenue of $14.61–$14.79 billion, representing 5.4% growth at the midpoint.
Labcorp Business Model Explained
Labcorp operates a laboratory services business model that generates revenue from diagnostic testing and biopharma laboratory services. The company invests in automation, artificial intelligence, and operational efficiency through its LaunchPad initiative to reduce costs and improve turnaround times. Capital allocation balances growth investments in specialty testing and acquisitions with shareholder returns through dividends ($2.88 per share annually) and share repurchases ($450 million in 2024). The balance sheet carries $5.05 billion in debt and $1.52 billion in cash, with investment-grade credit ratings supporting access to capital markets.
Labcorp Key Acquisitions
Labcorp's acquisition history reflects the consolidation of the clinical laboratory industry. The 2015 Covance acquisition ($6.1 billion) transformed the company into an integrated diagnostics and drug development leader. The 2016 Sequenom acquisition strengthened prenatal and genetic testing. The 2022 Personal Genome Diagnostics acquisition added precision oncology capabilities. In 2024, Labcorp acquired select Invitae assets (oncology and rare disease genetics) and BioReference Health's diagnostic business. These tuck-in acquisitions expand specialty capabilities and geographic presence without the integration complexity of transformative deals.
What Are the Biggest Risks Facing Labcorp?
Labcorp's biggest risks include Medicare PAMA reimbursement cuts compressing routine testing margins; commoditization of basic laboratory services by payers seeking lowest-cost providers; intense competition from Quest Diagnostics in a duopolistic market; cyclical exposure of Biopharma Laboratory Services to pharmaceutical R&D spending; potential FDA regulation of laboratory-developed tests; and disintermediation from point-of-care diagnostics and consumer-direct testing. The company must grow specialty testing and health system partnerships fast enough to offset routine testing price declines.
Bottom Line
Labcorp is growing, with FY2024 revenue up 6.6% to $13.01 billion and 2026 guidance for 5.4% revenue growth. The company's scale advantages in diagnostic testing, longitudinal patient data, and specialty testing expansion position it for continued growth. However, routine testing commoditization and Medicare reimbursement pressure create margin headwinds that specialty testing growth and LaunchPad cost savings must offset. The Biopharma segment's $7.9 billion backlog provides stability, but its lower margins and R&D cyclicality limit earnings contribution. Labcorp must prove it can evolve from a laboratory services company into a healthcare data and analytics platform to command premium valuations.
